Advertisement
Advertisement
Trending on Urology Times
1
Rethinking Testosterone Therapy After the FDA Label Revisions
2
Cretostimogene reduces recurrence risk by 68% in phase 3 PIVOT-006 trial in NMIBC
3
BPH treatment patterns: Understanding regional differences in baseline ED treatment
4
FDA clears phase 1/2 trial of androgen receptor antagonist in mCRPC
5
